Thursday, October 11, 2012

Super Hot Stock for Friday 10/12 - CLWR

CLWR - Close @ $ 2.2 with a monster 170 Million Volume..

10/12 Press Release

Softbank interested in buying Clearwire, CNBC's Faber reports

More from Reuters this evening

Reuters TOKYO/NEW YORK | Thu Oct 11, 2012 5:27pm EDT - Japanese wireless service provider Softbank Corp is looking to buy roughly 70 percent of Sprint Nextel Corp in a bold move that would make it a major player in the U.S. mobile market. 

http://www.reuters.com/article/2012/10/11/us-sprint-softbank-idUSBRE89A0I520121011 

But Softbank's ambitions may not stop with Sprint, which might also be looking to buy out its partner, Clearwire Corp. The Japanese company might also be aiming to use Sprint as a vehicle to make a run at smaller Sprint peer MetroPCS Communications Inc, a two-step transaction that would potentially cost more than 2 trillion yen ($25.55 billion), according to a Nikkei report. 

That would make it the biggest overseas acquisition by a Japanese company ever and vault Softbank into the upper echelons of wireless carriers worldwide. 

In response to reports of a pending deal, Sprint said on Thursday that it was in talks with Softbank on a "potential substantial investment" that could involve a change in control of the U.S. company. It said there was no assurance of a sale. 

Softbank is eyeing a controlling stake in Sprint worth more than 1 trillion yen ($12.8 billion) and is in talks with several banks to borrow money to finance a bid, according to a source with direct knowledge of the matter. 

A second source familiar with the situation, who would not speak on the matter publicly, said Softbank was after a stake of roughly 70 percent, which it could achieve by buying some newly issued shares directly from Sprint and tendering for the rest. 

By raising some new equity directly, Sprint would be able to shore up its balance sheet and potentially fund other deals such as a buyout of Clearwire in which it already holds roughly 48 percent. 

Sprint shares rose as much as 19 percent on Thursday to levels not seen since the summer of 2011, on the heaviest trading volume in the stock's history. The stock ultimately closed 14.3 percent higher at $5.76 on New York Stock Exchange. 

The shares of Clearwire, which could play a key role in any deal, closed almost 71 percent higher at $2.22. Clearwire, which has been looking for new sources offunding, has said that it has enough money until at least the middle of 2013. 

It declined to comment on Thursday and its chief financial officer pulled out of a conference presentation at the last minute without an explanation. 

A major Sprint investor said any Softbank investment should be used to buy out the rest of Clearwire, to give Sprint attractive wireless spectrum assets and to speed up Clearwire's upgrade of its wireless network with faster data speeds. 

"I just don't think there's any deal unless it involves Clearwire. I don't think you'd see one without the other," said Daniel Martino, a fund manager at T. Rowe Price, which owned 47.2 million Sprint shares as of the end of June. 

DEALS MULTIPLYING 

Sprint, whose market capitalization was $15.12 billion at Wednesday's market close, is the third-largest U.S. carrier, with more than 56 million users at the end of June, even after losing customers for years. 

As for Softbank, Sprint might be its only option for an entrance into the U.S. market, according to analysts. 

"In terms of (Sprint) standalone, we believe the asset represents the only way for a potential new entrant to get a national presence immediately in the U.S.," Wells Fargo analyst Jennifer Fritzsche wrote in a note to clients. 

The Softbank news comes just days after a source told Reuters that Sprint has been considering bidding for MetroPCS, which agreed this month to merge with Deutsche Telekom AG's and NTT Docomo. 

Japanese media said buying Sprint - which competes in the United States against Verizon Wireless and AT&T Inc - would also make it cheaper for Softbank to procure smartphones and other mobile devices. 

Benjamin Powell, a former general counsel to the director of national intelligence now in private practice at WilmerHale, said the deal was very likely to require a government review because it involved sensitive telecommunications networks. But several analysts said regulators were likely to eventually look favorably on a deal. 

Japanese companies made a record 642 cross-border deals last year, according to Thomson Reuters data. Buoyed by a stronger yen, the value of all overseas deals rose to $69.5 billion, up 81 percent from 2010, also a record. 

(Additional reporting by Mari Saito and James Topham in Japan, Sruthi Ramakrishnan in Bangalore, Soyoung Kim and Martinne Geller in New York, Rachelle Younglai in Washington and Carey Gillam in Overland Park, Kansas; Writing by Ian Geoghegan and Ben Berkowitz; Editing by Bernadette Baum, Andre Grenon and John Wallace) 

Wednesday, October 10, 2012

2 Hot Stocks for Rest of the 10/12 week

1. ONCS - Closing Price @ .37 on 10/10

Why this stock is getting sudden spike in the volume and the price. Please read below.

About the company

OncoSec Medical Incorporated is an emerging drug-medical device company. The Company focused on designing, developing and commercializing medical approaches for the treatment of solid cancers. In March 2011, the Company acquired from Inovio Pharmaceuticals, Inc. (Inovio) certain assets related to the use of drug-medical device combination products for the treatment of different cancers. The Company’s acquired assets relate to certain non-deoxyribonucleic acid (DNA) vaccine technology and property relating to selective tumor ablation technologies, which it refers to as the OncoSec Medical System (OMS), a therapy which uses an electroporation device to facilitate delivery of chemotherapy agents, or nucleic acids encoding cytokines, into tumors and/or surrounding tissue for the treatment and diagnosis of various cancers. As of January 24, 2012, the Company had not generated any revenue from operations.

What's the catalyst for this Spike


SAN DIEGO, Oct. 09, 2012 /PRNewswire/ -- OncoSec Medical Inc. (ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapies to treat solid tumor cancers, announced the company will be presenting data at two upcoming medical conferences.
Dr. Shailender Bhatia, assistant professor at the University of Washington School of Medicine, will be presenting preliminary clinical data from OncoSec's ongoing Phase II Merkel cell carcinoma trial at the 27th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2012), October 26-28, 2012, at the Bethesda North Marriott Hotel & Conference Center in North Bethesda, Maryland.
The company will also be presenting preliminary clinical data from its ongoing Phase II metastatic melanoma trial to the 6th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centres/8th EADO Congress, November 14-17, 2012, at the Hotel Fira Palace in Barcelona, Spain.
Preliminary analyses of both the Merkel cell carcinoma and metastatic melanoma trials will be based on a subset of enrolled subjects, and will evaluate clinical response to at least one cycle of ImmunoPulse treatment.
At the Melanoma/EADO meeting on November 15 at 5:30 PM local Barcelona time, Adil I. Daud, M.D., co-director of melanoma clinical research at the University of California San Francisco's Helen Diller Family Comprehensive Cancer Center and lead investigator for OncoSec's metastatic melanoma trial, along with Axel Hauschild, M.D., professor of dermatology at the University of Kiel, will co-chair an OncoSec-sponsored symposium titled "Electrogenetherapy: Intralesional Immunotherapy Approach for Skin Cancers Using Electroporation."
The company will provide a complete summary of the data presented at both conferences in upcoming press releases.


My Take on the Share price and action for rest of the week

Company CEO completed his presentation in Swiss Stock exchange.. See the tweet below


Presented at the Swiss Stock Exchange today. Next up, London Stock Exchange & NYSE EuroNext Paris!  

With lots of interest and the volume spike I see this closing @ or above 50 cents for the week with ease

2. PURE - Closing Price @ 1.26 on 10/10

This is a pure bottom bounce play closing @ 1.26 with the next resistance @ 1.75, which it will target for this week . Please see the chart below

http://stockcharts.com/h-sc/ui?s=pure


This stock is a perfect example of text book trading.. So play the dips and get ur 20% gains for this week

Happy Trading All ................... Adious





Monday, October 8, 2012

DCTH - $2.31 Rally Continues

DCTH - I alerted this stock @ 1.95 and today it closed @ 2.31 for a nice 11.5%. See the chart below

DCTH - Daily Chart

So what's next for this stock..

DCTH closed above 2.2 resistance which means that's the new first level of Support @ 2.2 and the resistance is @ 2.62 (200MA) which I will think it will breach by tomorrow EOD or Wednesday..........

NDA Acceptance is coming by Oct 15 which is providing to be a nice catalyst for this run... Check all the DCTH related news and articles in the link below

http://finance.yahoo.com/q?s=dcth&ql=1

Have a great rest of the week traders..................

Sunday, October 7, 2012

Trading Lessons - Part 1

From Claytrader - Master of chart Analysis

** Free Video Lesson: Justified Patience **
Here's the scenario. You buy a stock for the obvious reason that you believe it will go upwards in the future. Here's the dilemma, the not-so-obvious situation is 'how long' and 'when' is a "justified" time to sell and cut your loses?

Patience is no doubt a virtue and can lead to big profits in the world of the stock market; however, at the same time, unjustified patience can also not only cause you to lose money, but more importantly can waste your valuable time!

When is it "justified" to hang onto your positions, and at what point does it begin to become illogical? Watch this video lesson...

Watch here - http://www.youtube.com/watch?v=x1vLTPTA0HA&list=PLQPVUrXRarkvLGbTK9fXX3B37KybW01Mz&index=8&feature=plpp_video


** Free Video Lesson: The POWER of Volume **
Ever wondered how powerful of a technical indicator ‘volume’ could be? Check out this video to see a ‘real time’ example of how volume helped to forecast a monster move of over 400%!

http://www.youtube.com/watch?v=uG94rqqvlY8


** Free Video Lesson: What is Level 2? **
What the heck are Level 2's? What do they show you and what makes them move? All those answers and more in this two part lesson

http://www.youtube.com/watch?v=dWgdYw-YP7M - Part 1

http://www.youtube.com/watch?v=ObLp8_EFsaM - Part 2 

Saturday, October 6, 2012

DCTH - Hot stock in Play

DCTH - 2.07 - Stock to play till Oct 15 why? Please read below

The NDA acceptance will be in Oct 15 ( 2 months from the submission on Aug 15) and then they will appear again after acceptance. So now the Funds are jumping aboard now also known as the run up.
Now is the time to buy because there is least resistence from the shorts until the NDA acceptance.

How high can we go? Start buying and find out!!!!

After all DCTH will get priority review and acceptance.

How do i know you say? Does not matter. Get ready for next week

Chart Analysis - From yahoo board

DCTH made a new 5-month weekly closing high and closed on the highs of the week suggesting that this coming week it will break above the intra-week high for the same period of time at 2.24 and likely head up to at least the 50-week MA, currently at 2.65. The company is expecting to hear from the FDA by October 15th regarding the NDA it submitted and if the response is positive the stock will have strong fundamental reasons to continue to the upside. Above 2.24, resistance is decent at the 2.65 area from the 50-week MA as well as from 2 important highs seen in 2008 at 2.65 and at 2.67. Nonetheless, if that level is broken there is no resistance until 4.11 is reached. Support is now decent at 1.78 as that was the low for this week as well as where the 50 and 100 day MA’s are currently located. It should be mentioned that the bears were unable to close the breakaway gap down at 1.73 meaning that if another gap is seen on this rally it will be considered a runaway gap and will give strong impetus to further upside. If the stock is able to generate a daily close above 2.17, the 1.99 level will become decent daily close support. Probabilities favor further upside.